Drug Trial Radar · NCT07076199
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
877
Planned (sponsor's estimate)
Start
Aug 11, 2025
Primary completion
Jan 25, 2027
Study completion Mar 1, 2027
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jul 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.
Conditions
- Diabetes Mellitus, Type 1
Interventions
Insulin icodecDrug
Insulin icodec will be administered as subcutaneous injection
Insulin glargineDrug
Insulin glargine will be administered as subcutaneous injection.
Insulin aspartDrug
Insulin aspart will be administered as a subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in glycosylated haemoglobin (HbA1c)Time frame: From baseline (week 0) to week 26
Locations
182 sites in 8 countries. Site status is shown where the registry gives one.
Cullman Clinical Trials
Cullman, Alabama
John Muir Health
Concord, California
Headlands Research California, LLC
Escondido, California
Clinical Res of Central Ca
Fresno, California
Providence Medical Foundation
Fullerton, California
Scripps Whittier Diabetes Inst
La Jolla, California
Loma Linda University Faculty Medical Clinics
Loma Linda, California
Pacific Clinical Studies
Los Alamitos, California
Los Angeles Institute for Metabolic Research
Los Angeles, California
Pasadena Clinical Trials
Pasadena, California
WestenU Health
Pomona, California
Alliance Clinical Network
San Diego, California
Mills Health Center
San Mateo, California
Center for Endocrine DM and Metabolic Disorders
Santa Clarita, California
University Clin Investigators
Tustin, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Denver Endocrinology Diabetes and Thyroid Center
Englewood, Colorado
Optumcare Clinical Trials,LLC-Golden
Golden, Colorado
Northeast Research Institute
Fleming Island, Florida
Encore Medical Research LLC
Hollywood, Florida
Northeast Research Institute
Jacksonville, Florida
Life Spring Research Foundation LLC
Miami, Florida
Suncoast Clinical Research, Inc.
New Port Richey, Florida
West Orange Endocrinology
Ocoee, Florida
Suncoast Clinical Research, Inc.
Palm Harbor, Florida
Center for Diab,Obes & Metab
Pembroke Pines, Florida
SRA Trials-Broward
Pembroke Pines, Florida
Hanson Clinical Research Center
Port Charlotte, Florida
Latin Clinical Trial Ctr
Tamarac, Florida
Bayside Clinical Research
Tampa, Florida
Metabolic Research Institute Inc
West Palm Beach, Florida
Atlanta Diabetes Associates
Atlanta, Georgia
Centricity Research Columbus
Columbus, Georgia
Physicians Research Assoc. LLC
Lawrenceville, Georgia
Endocrine Research Solutions, Inc
Roswell, Georgia
Rocky Mt Clin Res, LLC
Idaho Falls, Idaho
Northwestern University
Chicago, Illinois
University Of Chicago
Chicago, Illinois
Endeavor Health
Skokie, Illinois
Indiana Uni School of Med-Ped
Indianapolis, Indiana
Showing 40 of 182 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.